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Background: Type 2 diabetes mellitus is increasing worldwide with an alarming rate. It is associated with the
development of various chronic complications. The aim of this study was to explore the alteration of pulmonary
function, and its association with renal complications in people with type 2 diabetes mellitus.
Methods: This cross-sectional study was conducted on three groups; 40 diabetic subjects without nephropathy
(urinary albumin<30 mg/day), 40 subjects with nephropathy (urinary albumin≥30 mg/day), and 40 healthy subjects
as the control group. The subjects with nephropathy were divided into those with microalbuminuria (urinary
albumin=30-300 mg/day) and those with macroalbuminuria (urinary albumin>300 mg/day) .Diabetic subjects were
matched to the control group in terms of age, sex, and BMI. Pulmonary function tests were performed and the
results were compared between groups.
Results: Forced vital capacity (FVC; % predicted), forced expiratory volume in 1 second (FEV1; % predicted), and
peak expiratory flow (PEF; % predicted) were significantly lower in subjects with diabetic nephropathy compared to
the healthy controls (P<0.05). Meanwhile, in diabetic subjects, FVC and FEV1 were lower in those with diabetic
nephropathy compared to those with normal albumin excretion (P<0.05). On the other hand, FEV1/FVC was
significantly higher in diabetic people with nephropathy.
Furthermore, a significant difference was observed between FVC and FEV1 in diabetic people with microalbuminuria
compared to those with macroalbuminuria.
Conclusions: This study showed that the pulmonary function was impaired in people with Diabetes. The progression
of diabetic nephropathy to more advanced stages was also associated with more impairment of pulmonary function.
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Type 2 diabetes mellitus is associated with the develop-
ment of micro- and macrovascular complications [1]. The
development of these complications can be explained by
the biochemical adjustment of connective tissue as well as
by microangiopathy due to protein glycosylation induced
by chronic hyperglycemia [2,3].
The pulmonary alveolar- capillary network represents
the largest microvascular structure in the body that could
be potentially affected by diabetic microangiopathy [4].
Some studies showed that in diabetic subjects, loss of
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reproduction in any medium, provided the or[5], chronic inflammation [6], autonomic neuropathy in-
volving pulmonary muscles, as well as microangiopathy of
the alveolar capillaries [1] can cause pulmonary dysfunc-
tion. However, pulmonary complications may be under-
diagnosed clinically [4]. It has also been demonstrated
that the pulmonary and other late complications of dia-
betes share a similar microangiopathic background [2,3].
An association between diabetic nephropathy and al-
teration of lung function had been described in type 1
diabetes [2]. However, in type 2 diabetes, limited studies
have been done to explore the alteration of pulmonary
function in the presence of diabetic nephropathy.
The aim of this study was to explore the effect of dia-
betic nephropathy on pulmonary function in people with
type 2 diabetes.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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This cross- sectional study was carried out from February
to Jul 2011 to assess pulmonary function in people with
type 2 diabetes compared with healthy individuals.
A total of 120 people were enrolled in the study using
consecutive sampling methods and comparison was done
among three groups, IE, diabetic people without nephrop-
athy, diabetic people with nephropathy, and healthy con-
trols. Nephropathy was defined as presence of ≥30 mg
albumin in a 24 hour urine sample collection, excluding a
falsely elevated urinary albumin excretion.
Those with history of cardiopulmonary, connective tis-
sue, overt renal disorders and end stage renal disease
(GFR < 60), patients with HbA1C>10% and Body mass
index ≥ 35 Kg/m2 were excluded as well as those with a
history of cigarette smoking at any time. All subjects in-
cluded did not have a history of chronic cough, sputum
production, dyspnea or any other systemic disorder that
may interfere with the results. The urinary albumin was
measured in the absence of urinary tract infection. The
patients with nephropathy were divided into those with
microalbuminuria (urinary albumin=30-300 mg/day) and
those with macroalbuminuria (urinary albumin>300 mg/
day). The serum levels of serotonin were within the nor-
mal range of all groups. Diabetic subjects were matched
to the control group in terms of age, sex, and BMI.
Weight was measured, while they were barefoot with
minimal clothing using digital scales and was recorded
to the nearest 100 g. Height was measured in a standing
position, without shoes, using a tape meter with shoul-
ders in normal alignment. Body mass index (BMI) was
calculated as weight in kilograms divided by height in
meters squared. To avoid interobserver error, all mea-
surements were taken by one person. Blood samples
were taken in a sitting position according to the stand-
ard protocol and centrifuged within 30-45 min of col-
lection. The analysis of samples was performed using
the selectra 2 auto-analyzer (Vital scientific, Spankeren,
Netherlands). Glycosylated hemoglobin (HbA1C) was mea-
sured using ion exchange chromatography (DS5 Analyzer,
Drew Scientific Limited, Cumbria, U.K). The urinary al-
bumin concentration was measured by nephelometric
method.
Pulmonary function tests were performed in the morn-
ing between 9:00-11:00 AM in a sitting position after a
resting period, using a standard spirometer (ML3500 MK8
MicroLab Spirometer U.K). Spirometry was performed by
trained and certified pulmonary technicians in accordance
with the American Thoracic Society Guidelines [7]. Mea-
sured parameters were forced vital capacity (FVC), forced
expiratory volume in 1 second (FEV1), vital capacity (VC)
and peak expiratory flow (PEF). The highest value for each
volume from three technically acceptable maneuvers were
used for evaluation [8].The values expressed as percentage of the predicted
normal value [9] were calculated for these parameters.
Informed consent was obtained from those eligible
subjects who desired to participate in the study. Ethical
approval was granted from research Ethics' committee of
Institute of Endocrinology and Metabolism, Tehran Uni-
versity of Medical Sciences.
Statistical analysis
All data are shown as mean ± SD unless otherwise
stated. Statistical evaluation was performed by analysis
of variance for continuous and chi- square test for cat-
egorical variables. The statistical analysis of the percent
predicted values of respiratory parameters tests was used
for the explanation of the results. Differences in pulmon-
ary function parameters between patients with and with-
out albuminuria were examined using multivariable linear
regression, adjusting for age and sex. To identify the vari-
ables most strongly associated with spirometric measures,
a linear regression model was fitted considering age, gen-
der, HbA1C, duration of diabetes and albuminuria as in-
dependent variables.
SPSS for Windows (version 16; SPSS Inc., Chicago,
ILL) was used for data analyses and P-values <0.05 were
considered as statistically significant.
Results
Forty diabetic people without albuminuria (62.5% fe-
male), 40 diabetic people with albuminuria (60% female),
and 40 healthy individuals (42.5% female) were enrolled
in this study. Among those with albuminuria, 36.2% had
microalbuminuria and 13.8% had macroalbuminuria. The
mean age of the participants was 53.6±11.9 years, and the
mean for BMI was 28.8±4.1 kg/m2. Table 1 shows
the baseline characteristics of the study population.
Diabetic people with normoalbuminuria were slightly
younger, and had a shorter duration of diabetes as com-
pared with diabetic people with albuminuria, but there
was no statistically significant difference in baseline
characteristics of the participants.
Pulmonary function parameters of the type 2 diabetic
people and healthy individuals are shown in Table 2.
Comparing with the healthy controls, significant reduc-
tion of FVC (% predicted), FEV1 (% predicted), and PEF
(% predicted) were found in diabetic people with ne-
phropathy (P<0.05). FVC (% predicted P<0.001), and
FEV1 (% predicted P<0.05) were lower in diabetic people
with nephropathy compared to those with normal
renal albumin excretion. On the other hand, FEV1/FVC
(% predicted P<0.05) was significantly higher in subjects
with nephropathy than these without nephropathy. After
adjustment for sex and age the FVC, FEV1 and PEF
remained significantly lower in people with nephropa-
thy (P<0.05).
Table 1 Baseline characteristics of the study population
Diabetics Non diabetics P value*
Normoalbuminuria (n=40) Albuminuria (n=40) (n = 40)
Male (%) 37.5 40 47.5 NS
Age (years) 52.0±11.5 55.2±12.3 51.9±7.2 NS
Height (cm) 159.7±9.7 158.5±8.1 160.1±8.7 NS
Weight(kg) 72.7±12.9 73.0±10.7 74.2±13.4 NS
Body Mass Index (kg/m2) 28.5±4.0 29.1±4.2 27.4±3.6 NS
Duration of diabetes (years) 8.9±5.7 10.8±7.2 ———————
HbA1C (%) 8.4±2.0 8.4±1.9 ————————
Albumin excretion rate (mg/24 h) 18.8±1.2 334.4±88.9 ————————
Data are means (SD) unless indicated otherwise. NS: Non Significant.
*P value (Non diabetics vs. all diabetic patients).
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monary function parameters (FVC, FEV, FEV1/FVC), ex-
cept PEF, independent of other risk factors (P<0.05)
(Table 3).
Figure 1 compares the differences of pulmonary func-
tion parameters according to albuminuria in diabetic
people. As the figure illustrates, the mean percent pre-
dicted values were 90.91% ± 14.21 vs. 103.07% ± 9.90,
P<0.05 for FVC, and 93.82 ± 15.02 vs. 104.38 ± 12.02,
P=0.05 for FEV1, in patients with macroalbuminuria and
with microalbuminuria, respectively.
Discussion
The results of the present study indicate that the pul-
monary dysfunction is more pronounced in subjects
with diabetic nephropathy, independent of other risk
factors. Moreover, the progression of nephropathy to the
more advanced stages was also associated with more im-
pairment of pulmonary function.
Our results are generally consistent with prior studies,
which demonstrated lower FVC and FEV1 in adults with
diabetes as compared to non-diabetic counterparts [10,11].
People with diabetes are at increased risk of micro-
vascular complications. The main reasons of these com-
plications are connective tissue changes as a result of
microangiopathy due to glucosylation of proteins induced




FVC (predicted %) 115.45(16.44) c
FEV1 (predicted %) 112.67(16.24)b
PEF (predicted %) 90.95(17.37)
FEV1/FVC (predicted %) 102.55(7.26)b
Data are mean(SD), FVC: Forced Vital Capacity, FEV1: Forced Expiratory Volume in 1
Diabetic people versus healthy individuals: a P<0.05.
Diabetic people with no albuminuria versus those with albuminuria: b P<0.05; c P<0review, Klein et al showed that lung is a large microvascu-
lar organ and may be affected by microangiopathy in dia-
betic people [12]. Adults with diabetes have decreased
lung function compared with adults without diabetes, re-
gardless of other risk factors. The most important risk
factors are glycemic control and diabetes duration. How-
ever, along with the presence of external risk factors,
some associations have also been noted considering dia-
betes complications [10,13].
The Diabetes Control and Complications Trial (DCCT)
demonstrated that there was a strong relationship be-
tween diabetic retinopathy and elevated albumin excre-
tion [14]. The EURODLAB study showed that diabetic
retinopathy, in association with increased blood pressure,
is an important independent risk factor for diabetic ne-
phropathy progression [15].
In addition, it has been demonstrated that the pul-
monary and other organ systems of people with diabetes
share a similar microangiopathic background. There is
strong epidemiological evidence that peak expiratory flow
rate is decreased in diabetic people with microvascular
complications compared to those without microvascular
complications [16].
Chronic complications of diabetes have relatively simi-
lar frequency and severity which might be due to an iden-
tical mechanism. Postmortem studies of diabetic people
showed an increased thickness of the alveolar wall andd healthy individuals
iabetic Nondiabetics
Albuminuria (n = 40)
(n=40)




s, PEF: Peak Expiratory Flow.
.001.
Table 3 The effect of albuminuria on pulmonary function
parameters in diabetic people after adjusting other risk
factors*
β S.E P value
FVC (predicted %) −0.51 4.10 <0.001
FEV1 (predicted %) −0.37 3.91 0.006
PEF (predicted %) −0.22 4.76 0.11
FEV1/FVC (predicted %) 0.29 1.97 0.02
* linear regression model after adjusting for age, sex, Glycosylated hemoglobin
(HbA1C), and duration of diabetes.
FVC: Forced Vital Capacity, FEV1: Forced Expiratory Volume in 1s, PEF: Peak
Expiratory Flow.
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limitation of lung expansion and reduction in the ventila-
tory capacity. In the kidney, thickness of glomerular capil-
laries causes impaired selectivity for proteins and an
increase in albumin excretion rate. All these support the
importance of an etio-pathologic mechanism in the devel-
opment of diabetic microvascular complications [11,17].
In previous studies, a marked alteration of the pul-
monary function was found in type 1 diabetic patients
with end- stage renal disease, suggesting a high preva-
lence of restrictive pulmonary disease in the presence of
diabetic nephropathy [9,18], To our knowledge there are
a few studies about the effect of diabetic nephropathy in
its earlier stages on pulmonary function especially in
type 2 diabetic people. In the current study, the signifi-
cant reduction of pulmonary function parameters was
more pronounced in patients with albuminuria compar-
ing to those with normal urinary albumin excretion.
Some clinical studies have found that pulmonary func-
tion parameters in people with diabetes are inversely
correlated with glycemic control, duration of diabetes,
and its severity. Some other risk factors including age,






Figure 1 Pulmonary function parameters according to albuminuria in
Volume in 1s, PEF: Peak Expiratory Flow. * P<0.05, Diabetic people with no
macroalbuminuria). † P<0.05, Diabetic people with macroalbuminuria vs. thIn the Framantle Diabetes Study [10], diabetes duration
was more influential than the state of glycemic control.
Obesity and vascular disease were independently and in-
versely associated with spirometric parameters. In our
study, presence of diabetic nephropathy was associated
with reduced pulmonary function parameters whereas
other risk factors such as duration of diabetes and
HbA1C were not. Although a relationship between gly-
cemia and impaired lung function could be present in
diabetic patients, our data provide some evidence that
existing microvascular complication may be more im-
portant than other pulmonary risk factors. Although
suggested mechanisms for impaired pulmonary function
in diabetic patients include glycosylation of proteins, the
lack of association of pulmonary parameters with gly-
cemic control and duration of diabetes in this study,
shows a more complex model of diabetic complications-
related pulmonary damage. Among the main mecha-
nisms, systematic and local inflammation [6], autonomic
neuropathy involving the respiratory muscles [19], and
hypoxia- induced insulin resistance could be responsible
for impaired pulmonary functions [20]. Left ventricular
diastolic dysfunction observed in diabetic people with
microalbuminuria, and central volume expansion may
provide pulmonary impairment in patient with albu-
minuria [21]. As diabetic complications are interrelated,
early detection of microvascular disease in its earliest
stages might be beneficial [22].
There are some limitations that should be considered
when examining the results of this study. The first limi-
tation is the use of a cross- sectional design to find the
pulmonary impairment in diabetic patients with albu-
minuria. Secondly, the sample size was fairly small and
limited the power to recognize small differences between
groups. The other limitation was excluding patients with
cardiopulmonary disorders just based on history taking.00 120 140
Diabetic without Albuminuria
Diabetic with Macroalbuminuria mean
Diabetic with Microalbuminuria mean
diabetic people. FVC: Forced Vital Capacity, FEV1: Forced Expiratory
albuminuria versus those with albominuria (micro and
ose with microalbuminuria.
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buminuria and reduced pulmonary function was not
explained by concurrent respiratory infections or heart
failure. We also showed that progression of diabetic ne-
phropathy was associated with more deterioration of
pulmonary function.
Conclusion
Our findings showed that the pulmonary function was im-
paired in people with diabetes. The severity of pulmonary
dysfunction seems to be correlated with the severity and
stage of diabetic nephropathy. Longitudinal studies are
needed to examine pulmonary function in diabetic people
as a marker of microvascular involvement in diabetes.
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